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Combined MAPK/PI3K pathway inhibition represents an attractive, albeit toxic, therapeutic strategy 
in oncology. Since PTEN lies at the intersection of these two pathways, we investigated whether PTEN 
status determines the functional response to combined pathway inhibition. PTEN (gene, mRNA, and 
protein) status was extensively characterized in a panel of cancer cell lines and combined MEK/mTOR 
inhibition displayed highly synergistic pharmacologic interactions almost exclusively in PTEN-loss 
models. Genetic manipulation of PTEN status confirmed a mechanistic role for PTEN in determining 
the functional outcome of combined pathway blockade. Proteomic analysis showed greater 
phosphoproteomic profile modification(s) in response to combined MEK/mTOR inhibition in PTEN-
loss contexts and identified JAK1/STAT3 activation as a potential mediator of synergistic interactions. 
Overall, our results show that PTEN-loss is a crucial determinant of synergistic interactions between 
MAPK and PI3K pathway inhibitors, potentially exploitable for the selection of cancer patients at the 
highest chance of benefit from combined therapeutic strategies.
Cancer is increasingly recognized as a signaling disease. The RAF/MEK/ERK (MAPK) and PI3K/AKT/mTOR 
(PI3K) pathways cooperate to govern fundamental physiological processes, such as cell proliferation, differentia-
tion, metabolism and survival1–3. Constitutive activation of one or both these pathways is a commonly occurring 
event and has been implicated in the initiation, progression and metastasis of solid and hematologic malig-
nances4–8. Extensive cross-talk occurs between the MAPK and PI3K pathways, but their relationship is complex, 
so that pharmacologic interference at a single point of the network may actually result in the “paradoxical”, and 
often “undesired” from a therapeutic point of view, activation of the same or the alternative pathway, thereby 
leading to cancer cell survival and drug resistance9–11.
In this context, combined inhibition of both MAPK and PI3K is being tested as a potential strategy to over-
come/delay resistance and widen the scope of sensitive cancer patients4,9,10,12–16. However, combined pathway 
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inhibition in the clinical setting often requires substantial reductions of each single agent dose. Moreover, this 
type of strategy implies increased monetary and toxicity costs, which represent a high risk for both individual 
patients and the society as a whole, should it fail to demonstrate more than additive benefits. Thus, the identifi-
cation of putative biomarkers of synergistic therapeutic interactions will be crucial to successfully develop com-
bination strategies in the clinical setting, allowing for the selection/enrichment of patients who are most likely to 
benefit12,17,18.
Our group has recently reported on a novel crosstalk mechanism between the MAPK and PI3K pathways, 
whereby constitutive ERK activation represses PTEN expression in melanoma and other cancer models. These 
findings bear important functional consequences, since in cellular contexts in which PTEN is unaltered MEK 
blockade leads to increased PTEN protein expression, which plays an important, albeit not exclusive, role in the 
antitumor and anti-angiogenic activities of MEK inhibitors9,10.
Based on this rationale, we evaluated the role PTEN status has in modulating the growth inhibitory activity 
of single or combined MEK and mTOR inhibition. Our results show that growth inhibitory synergism with com-
bined MAPK/PI3K inhibition is almost invariably observed in cells with PTEN-loss, but not in tumor cells with 
an intact PTEN. PTEN expression or lack thereof causally modifies both signaling perturbations and functional 
responses induced by combined MEK and mTOR inhibition, suggesting that PTEN-loss maybe proposed as a 
potential selection/stratification factor for clinical trials employing such combinations.
Results
PTEN profiling in human cancer cell lines. To investigate the role of PTEN in modulating the response 
to MAPK or PI3K pathway inhibition, panels of thirty tumor cell lines of different histological origin (melanoma, 
n = 7; breast cancer, n = 6; non-small cell lung cancer, n = 6; colorectal cancer, n = 8; pancreatic adenocarcinoma, 
n = 2; glioblastoma, n = 1; Table 1) were analyzed for PTEN gene status. To this purpose, DNA extracted from 
each sample was amplified by multiplex PCR for the PTEN gene and an adequate library for deep sequencing was 
obtained. The mean read length was 101 base pairs and a mean coverage of 1823× was achieved, with 94.5% tar-
get bases covered at more than 100× . A minimum coverage of 50× was obtained in all cases. Results are summa-
rized in Table 1. PTEN expression was further analyzed at the mRNA and protein levels by RT-qPCR and Western 
blotting in all cell lines. As shown in Fig. 1 and summarized in Table 1, PTEN protein expression was completely 
absent (score 0, - in Table 1) in 9/30 tumor cell lines; among 21 cell lines with PTEN protein expression, PTEN 
expression was weak (score 0.1–0.3, +  in Table 1) in 10, moderate (score 0.3–0.6, + + in Table 1) in 9, and strong 
(score 0.6–1, + + + in Table 1) in 2. Statistical analysis showed a moderate correlation between PTEN mRNA and 
protein expression levels (p = 0.038, Figure S1).
In order to define PTEN expression profile unequivocally, we considered cell lines with any degree of PTEN 
protein expression (score 0.1–1) in the absence of PTEN gene alterations as PTEN-competent, while cell lines 
carrying PTEN deletions or inactivating mutations or completely lacking PTEN protein expression (score 0) are 
referred to as PTEN-loss (see also Table S1).
PTEN expression modulates sensitivity to MEK, but not to mTOR, inhibition. Tumor cell lines 
characterized for the mutational status of KRAS, BRAF, and PTEN (Table 1 and S1) were exposed to either 
the MEK inhibitor Trametinib or the mTOR inhibitor Everolimus (both at concentrations ranging from 0.1 to 
1000 nM) for 72 h and half maximal inhibitory concentration (IC50) were derived, based on the assessment of 
cell viability (Table S1). Neither BRAF, KRAS or PTEN mutational status appeared to significantly influence 
response to Trametinib (p = 0.24, p = 0.10 and p = 0.15, respectively, Figure S2A) or Everolimus (p = 0.46, 
p = 0.48 and p = 0.79, respectively, Figure S2B). In order to ascribe a mechanistic role to PTEN expression in 
determining functional response to MEK or mTOR inhibition, we silenced PTEN expression by shRNA in 
the PTEN-competent melanoma cell line M14 (clone M14/shPTEN, Figure S2C insert) and overexpressed a 
functional PTEN in the PTEN-loss melanoma cell line WM115 (clone WM/PTEN, Figure S2D insert). PTEN 
silencing rendered M14 cells more resistant to Trametinib, as shown by both dose-response and growth curves 
(Figures S2C and S3A), with a slight shift in the IC50 at 72 h (from 0.3 nM in M14 to 1 nM in M14/shPTEN). In 
WM115 cells, stable transfection with a GFP-tagged PTEN construct, slowed down basal growth rate (doubling 
time ~40 h in WM115 and 51 h in WM/PTEN, respectively; Figure S3B) and rendered cells remarkably more 
sensitive to Trametinib-induced growth inhibition (IC50 4000 nM versus 0.06 nM in WM115 and WM/PTEN, 
respectively; Figures S2D and S3B). Conversely, no striking differences were observed in response to Everolimus 
exposure in either model (Figures S2C,D and S3A,B).
From a molecular perspective, we analyzed the effects of Trametinib and Everolimus on the phosphoryla-
tion of key mediators of the PI3K and MAPK pathways (Figure S4). As expected, after 24 hours of treatment 
Trametinib efficiently blocked ERK phosphorylation, while Everolimus increased AKT T308 and S473 phospho-
rylation. However, no major qualitative differences were noted in terms of perturbation of signaling induced by 
MEK or mTOR blockade according to PTEN expression.
Analysis of pharmacological interactions between MEK and mTOR inhibitors according to 
PTEN status. The effect of combined treatment with Trametinib and Everolimus, using a fixed dose-ratio 
(1:1) experimental design over a wide range of concentrations (0.1–1000 nM) of each agent, was assessed in vitro 
on the same panel of 30 human cell lines (Table S1). As shown in Fig. 2A, pharmacologic interactions between the 
two agents were almost invariably synergistic in cells with PTEN-loss, while combined MEK/mTOR inhibition 
resulted in a slightly additive/frankly antagonistic growth inhibitory response in PTEN-competent tumor cells, 
with the notable exception of the H460 lung cancer cell line, where combined treatment achieved strongly syn-
ergistic growth inhibition, despite the presence of an intact PTEN gene and protein. Overall, PTEN-loss (but not 
BRAF or KRAS mutations, p = 0.91 and p = 0.40, respectively, data not shown) was significantly associated with 
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a synergistic interaction between Trametinib and Everolimus (p < 0.0001; Fig. 2B). Two representative examples 
of additive/antagonistic pharmacologic interactions between Trametinib and Everolimus in PTEN-competent 
(M14 and ME8959) and of synergistic growth inhibitory response in PTEN-loss (WM115 and C32) melanoma 
models are reported in Figure S5.
We also set out to confirm the pharmacologic interactions observed in vitro between Trametinib and 
Everolimus in xenograft models in vivo (Fig. 2C). In particular, established M14-derived (PTEN-competent) 
or C32-derived (PTEN-loss) xenografts were treated with Trametinib and Everolimus, alone or in combination, 
for up to 13 days and the effects on tumor growth were evaluated at the point of maximum tumor inhibition. In 
the M14-derived model Trametinib, used as single agent, significantly inhibited tumor weight (p = 0.03 versus 
control). In this context, Everolimus had no significant effect, as either single agent (p = 0.1 versus control) or 
in combination with Trametinib (p = 0.56 versus Trametinib alone). Conversely, in the C32-derived model the 
combination of Trametinib and Everolimus had a significantly greater tumor growth inhibitory effect, as com-
pared to each treatment alone (p = 0.02 for the comparison between Trametinib and combination; p = 0.01 for 
the comparison between Everolimus and combination; Fig. 2C).
We next analyzed the effects of combined MEK/mTOR inhibition on the expression of key apoptosis regula-
tors by immunoblotting (Figure S5C). In both M14 (PTEN-competent) and WM115 (PTEN-loss) we observed 
Bim induction, caspase 3/7 and PARP cleavage following treatment with Trametinib; however, the addition of 
Cell Line MUT PTEN status COSMIC ID PTEN CNV
PTEN PTOTEIN 
EXPRESSION*
Relative 
PTEN mRNA 
abundance**
Melanoma
 WM115 LOH§ − 0.14
 ME8959 LOH§ + + 0.21
 ME4686 Pro38Ser COSM5142 LOH§ + 0.22
 ME1007 + + 0.62
 M14 + 0.13
 ME1 + 0.73
 C32 LOH§ − 0.03
Breast
 BT474 + + 0.06
 BT549 − 0.15
 AU565 + 0.02
 MDA-MB468 253+ 1 G > T (splice site donor) COSM13730 − 0.32
 MDA-MB436 LOH§ − 0.51
 MDA-MB361 + + 0.88
Lung
 NCI-H1650 LOSS − 0.04
 NCI-H1975 GAIN (3) + + 0.65
 Calu-1 + 0.63
 Calu-3 + 0.1
 NCI-H460 + + + 0.26
 A549 + 0.31
Colon
 KM12C Gly129Ter; Lys267ArgfsTer9 COSM18663 − 0.20
 SW620 GAIN (3) + + 0.41
 HT29 + + 0.40
 MSDT8 Asp310Gly COSM1968270 − 0.01
 RKO + 0.12
 HCT116 + + 0.35
 HCT116 Parental + + 0.39
 HCT116 PTEN−/− frameshift_variant, stop_lost − 0.23
Pancreas
 MiaPaCa + 0.36
 HPAF II + 0.74
Glioblastoma Positive Control
 T98G Leu42Arg COSM5269 + + + 1
Table 1.  PTEN status in cancer cell lines. *OD ratio of PTEN antibody/β -actin for each individual sample is 
compared with OD of positive control T98G. + score 0.1–0.3; + + score 0.3–0.6; + + + score 0.6–1. **Results 
represent PTEN mRNA abundance relative to positive control T98G. Abbreviation used in the Table: LOH, Loss 
of heterozygosity.
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Everolimus slightly increased caspase 3/7 and PARP cleavage only at the 24 h time point in M14, while substan-
tially increased apoptosis induction in WM115 at both 24 and 48 hours, suggesting that synergistic effects of the 
combination in PTEN-loss contexts are due, at least in part, to apoptosis induction.
PTEN status causally affects response to combined MEK/mTOR inhibition. The potentially causal 
role of PTEN in determining the functional outcome of combined MEK and mTOR inhibition was assessed in 
an isogenic colon cancer cell line model, differing only for PTEN status: Fig. 2D,E shows the growth inhibitory 
response (top panel) and pharmacologic interactions (expressed as combination index - CI - versus fraction 
affected, bottom panel) observed with Trametinib and Everolimus in the X-MAN™ isogenic HCT116 cell lines. 
The growth inhibitory effect of combination treatment was additive in HCT116 Parental (PTEN-competent, aver-
age CI at the ED50, ED75, and ED90: 1) and strongly synergistic in HCT116 PTEN−/− (PTEN-loss, average CI at the 
ED50, ED75, and ED90: 0.25), respectively; similar results (additive/antagonistic interactions in HCT116 Parental 
and highly synergistic interactions in HCT116 PTEN− /− ) were obtained using different Trametinib/Everolimus 
ratios (1:1, 100:1, or 1:100; Figure S6).
In order to validate the role of PTEN status in determining the response to combined MEK and mTOR inhi-
bition mechanistically, we performed combination experiments in M14/shPTEN and WM/PTEN (see also 
Figures S2 and S3). In the M14 model the combination of Trametinib and Everolimus did not afford increased 
growth inhibition, as compared to Trametinib alone (Fig. 3A, top panel). Conversely, in M14/shPTEN growth 
inhibition rates were significantly greater than those achieved with individual drugs (Fig. 3C, top panel). As 
a result, isobologram analysis indicated additive/antagonistic interactions in M14 cells and strong synergism 
between Trametinib and Everolimus in M14/shPTEN, with a CI of 1 and 0.3, respectively (Fig. 3A and C, bottom 
panels). On the other hand, combined Trametinib and Everolimus afforded significantly increased growth inhi-
bition, as compared to each agent alone, resulting in a highly synergistic pharmacologic interaction in WM115 
(Fig. 3B). In WM/PTEN, the introduction of a functional PTEN protein dramatically potentiated Trametinib’s 
growth inhibitory activity, which was only slightly increased by the addition of Everolimus (Fig. 3D, top panel). 
Figure 1. PTEN expression in different cancer cell lines. (A–E) The cells, divided according to histological 
origin, were lysed and analyzed by Western Blotting using antibodies specific for PTEN. Western blot with 
antibodies specific for β -actin are shown as protein loading and blotting control. The T98G cells were used as a 
positive control for PTEN expression. (F) The presence of PTEN was detected by real-time PCR in all cell lines 
analyzed previously. Results were evaluated as Δ Δ ct of PTEN tested relative to RPL19 and expressed as the 
ratio assuming the levels in T98G positive control cells as 1.0.
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Although the experimental points fall in the highly synergistic part of the curve in both cellular models, the 
CI/fraction affected curve obtained in WM/PTEN actually mirrors that obtained in empty vector-transfected 
WM115 cells (Fig. 3B and D, bottom panels), suggesting, once again, that PTEN status dramatically influences 
response to combined MEK and mTOR inhibition.
PTEN expression influences response to combined inhibition at different steps of the MAPK/
PI3K cascades. We next sought to ascertain whether the above-described findings on the influence of 
Figure 2. PTEN is a crucial determinant of synergism between MEK and mTOR inhibitors. (A) Growth 
inhibitory interactions between Trametinib and Everolimus were assessed in a panel of 30 tumor cell lines 
using a fixed-ratio (1:1) with a wide range of concentrations (0.1–1000 nM). Viability was then assessed after 
72 h by Crystal violet assay and pharmacologic interactions were evaluated using the Calcusyn software. By 
this method, an average combination index (CI) at the ED50, ED75, and ED90 < 1 indicates synergism, = 1 
indicates additivity, and > 1 indicates antagonism. (B) Box plot shows the relationships between Trametinib/
Everolimus pharmacologic interactions (CI) and PTEN status in a panel of 30 tumor cell lines. (C) Nude mice 
were injected i.m. with M14 (PTEN-competent) and C32 (PTEN loss) cells; when tumors became palpable, 
mice were treated with Trametinib 0.2 mg/Kg (Tram), Everolimus 2 mg/Kg (Eve) or their combination (Combo) 
for up 13 days. Differences in tumor weight after 7 (M14) or 10 (C32) days of treatment are shown. Tumor size 
was measured by caliper. Results from one representative experiment of at least two performed are shown and 
are expressed as average tumor weight (mg) ± SD for each treatment group. In M14-derived tumors: *p = 0.034 
(by 2-tailed Student’s t test) for the comparison between control and Trametinib-treated, **p = 0.056 for the 
comparison between control and combination-treated, ***p = 0.001 for the comparison between Everolimus- 
and combination-treated; all other comparisons, including comparison between Trametinib- and combination-
treated, were not significant. In C32-derived tumors: §p = 0.006 for the comparison between control and 
Trametinib-treated §§p < 0.01 for the comparison between control and combination-treated, Everolimus- and 
combination-treated, Trametinib- and combination-treated. (D,E) Isogenic HCT116 cell lines were treated 
with Trametinib and Everolimus, alone or in combination, using a fixed dose ratio (1:1). Cell viability was 
assessed by Crystal violet assay after 72 h. Results are expressed as percentage of growth inhibition relative to 
untreated control and represent the average ± SEM of three independent experiments (top). CI were plotted 
against the fraction affected (bottom). Asterisks indicate statistically significant differences (p < 0.05 by 2-tailed 
Student’s t test) for the comparison between *Everolimus- and combination-treated cells or **Trametinib- and 
combination-treated cells.
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PTEN status on the functional outcome of combined pathway inhibition would specifically apply to the com-
bination of MEK and mTORC1 inhibition. First, we substituted the selective BRAF inhibitor Dabrafenib for the 
MEK inhibitor Trametinib and tested it in combination with Everolimus in M14 and WM115 melanoma cells. 
Similar to the observations made with Trametinib, the combination of Dabrafenib and Everolimus exerted a 
synergistic growth-inhibitory effect only in PTEN-loss cells (WM115, CI: 0.7), while in the M14 model drug 
interaction was only additive (CI: 1) (Figure S7). We also tested a direct allosteric AKT inhibitor (MK-2206, 
dose-range 10–5000 nM) or a PI3K/mTOR double kinase inhibitor (PF-05212384, dose-range 0.1–1000 nM) in 
both M14 and WM115 cells, alone and in combination with Trametinib at a fixed dose-ratio (100:1 and 1:1, 
respectively). As shown in Fig. 4A,B, antagonistic/additive interactions were observed between MK-2206 and 
Figure 3. Genetic manipulation of PTEN expression modifies response to combined MEK/mTOR 
inhibition. (A–C) M14 clones stably transfected with either an empty plasmid vector (M14) or a plasmid 
encoding shPTEN (M14/shPTEN) were treated with Trametinib (Tram) and Everolimus (Eve), alone or in 
combination, using a fixed ratio (Combo 1:1). Cell viability was assessed by Crystal violet assay after 72 h. 
Results are expressed as percentage of growth inhibition relative to untreated control and represent the 
average ± SEM of three independent experiments (top). CI were calculated by conservative isobologram 
analysis for experimental data and plotted against the fraction affected (bottom). Asterisks indicate statistically 
significant differences (p < 0.05 by 2-tailed Student’s t test) for the comparison between *Everolimus- and 
combination-treated cells or **Trametinib- and combination-treated cells. (B–D) WM115 clones stably 
transfected with either an empty plasmid vector (WM115) or a plasmid encoding a GFP-tagged PTEN (WM/
PTEN) were treated with Trametinib (Tram) and Everolimus (Eve), alone or in combination using a fixed ratio 
(Combo 1:1). Cell viability was assessed by Crystal violet assay after 72 h. Results are expressed as percentage 
of growth inhibition relative to untreated control and represent the average ± SEM of three independent 
experiments (top). CI were calculated by conservative isobologram analysis for experimental data and plotted 
against the fraction affected (bottom). Asterisks indicate statistically significant differences (p < 0.05 by 2-tailed 
Student’s t test) for the comparison between *Everolimus- and combination-treated cells or **Trametinib- and 
combination-treated cells.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:43013 | DOI: 10.1038/srep43013
Trametinib (CI: 1) or PF-05212384 and Trametinib (CI: 1.1) in the PTEN-competent M14 cells, with slight syn-
ergism observed only with the combination PF-05212384/Trametinib at the highest concentrations. Conversely, 
Figure 4. PTEN status affects response to MEK inhibition in combination with either AKT or double 
PI3K/mTOR inhibition. (A,C) M14 (PTEN-competent, A) and WM115 (PTEN-loss, C) cells were exposed 
to increasing concentrations of Trametinib (0.1–1000 nM) and either the allosteric AKT inhibitor MK-2206 
(10–5000 nM) or the double PI3K/mTOR inhibitor PF-05212384 (0.1–1000 nM); combination experiments 
were performed using a fixed dose-ratio design using a 1:100 and 1:1 ratio, for Trametinib/MK-2206 and 
Trametinib/PF-05212384 combinations, respectively. Cells were exposed to treatments for 72 h and cell viability 
was assessed by Crystal violet assay (representative microscopic fields photographed are shown). Results of one 
experiment representing three independent experiments performed with superimposable results are shown. 
(B,D) CI were calculated by conservative isobologram analysis for experimental data and plotted against the 
fraction affected.
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the combination completely suppressed cell growth, resulting in a highly synergistic drug interaction (CI: 0.4 and 
0.05 for MK-2206/Trametinib and PF-05212384/Trametinib combinations, respectively) in the PTEN-loss cell 
line WM115 (Fig. 4C,D, bottom). Similar results were obtained in ME8959 (PTEN-competent; CI: 1 and 13.7 for 
MK-2206/Trametinib and PF-05212384/Trametinib combinations, respectively) and C32 (PTEN-loss; CI: 0.5 for 
both MK-2206/Trametinib and PF-05212384/Trametinib combinations) melanoma cell lines (data not shown).
Effects of combined MEK/mTOR inhibition in patient-derived CSC models. It has been reported 
that PTEN levels in cancer stem cells (CSC) are usually very low, as compared to more differentiated, “bulk” pop-
ulations or established cell lines, particularly in lung and colorectal cancer-derived models (recently reviewed in 
ref. 19). Thus, we investigated the response of patient-derived melanoma initiating cells (MIC, n = 5) or lung CSC 
(LCSC, n = 5)20,21 to Trametinib and Everolimus, either alone or in combination, in vitro (Fig. 5A and S8A,B). 
All of the MIC analyzed expressed PTEN protein (Figure S8C) and were sensitive to Trametinib, but the addition 
of Everolimus had no appreciable effect (Figure S8A), so that pharmacological interactions were in the antago-
nistic range (CI: 2.4 to > 109, data not shown). Conversely, PTEN protein is expressed at very low levels in LCSC 
(ref. 22 and Figure S8C) and the combination of Trametinib and Everolimus resulted in a strikingly synergistic 
growth-inhibitory interaction in vitro in three out of five LCSC tested (LCSC1: CI = 7 × 10−9; LCSC2: CI = 0.11; 
LCSC3: CI = 0.34; Fig. 5A and S8B). We next tested the effects of Trametinib (0.3 mg/kg) and Everolimus (2 mg/kg), 
given as daily oral gavage either alone or in combination for up to 4 weeks, in a patient-derived colorectal CSC 
(CR-CSC) xenograft model in vivo; as shown in Fig. 5B,C, tumor growth was significantly inhibited by Trametinib 
exposure (p = 0.0009), while Everolimus-treated tumors did not significantly differ from vehicle control-exposed 
tumors in either their final size or their growth rate; however, combined treatment with Trametinib and 
Everolimus resulted in highly significant growth inhibition, as compared to either vehicle control (p = 0.0001) 
or single agent treatment (p = 0.003 for the comparison between Trametinib and combination; p = 0.0026 for the 
comparison between Everolimus and combination). In vivo treatment with Trametinib and Everolimus, alone 
and in combination was well tolerated, as no macroscopic signs of toxicity were observed and mice weight was 
conserved across treatment groups (data not shown).
Proteomic Analysis. Protein expression profiles and changes in phosphorylation status at specific sites were 
assessed in WM115 and in WM/PTEN cells, after treatment with Trametinib, Everolimus or their combina-
tion, using antibody microarrays. A list of differentially expressed proteins identified as significantly modulated 
following at least one treatment is reported in Table S2. Principal Component Analysis (PCA) revealed more 
Figure 5. Effects of single and combined MEK and mTOR inhibition in LCSC. (A) Cells obtained from lung 
cancer spheres (LCSC) dissociation were plated in 96-well flat-bottom plates; Trametinib and Everolimus were 
added at their final concentration (1–1000 nM), as single agents or in a fixed dose-ratio combination (1:1). CI 
were calculated by conservative isobologram analysis for experimental data and plotted against the fraction 
affected. (B) Macroscopic image of subcutaneous tumor xenografts was obtained after injection of CR-CSCs. 
Mice were treated for 3 weeks with Vehicle or Placebo (Control or Eve placebo), Trametinib (Tram), Everolimus 
(Eve) alone or in combination (Tram/Eve). (C) Size of subcutaneous tumor xenografts was obtained in mice 
treated as in B. Data represents mean ± S.D. of three independent experiments. *p = 0.0009 for the comparison 
between control and Trametinib-treatment, **p for combined treatment with Trametinib and Everolimus as 
compared to either vehicle control (p = 0.0001) or single agent treatment (p = 0.003 for the comparison between 
Trametinib and combination, p = 0.0026 for the comparison between Everolimus and combination).
www.nature.com/scientificreports/
9Scientific RepoRts | 7:43013 | DOI: 10.1038/srep43013
extensive treatment-induced modifications in total and phosphorylated protein expression in WM115 cells, as 
compared to WM/PTEN (Fig. 6A), particularly after treatment with single-agent Trametinib or the combination 
of Trametinib and Everolimus. Unsupervised hierarchical cluster analysis (heath map) of all proteins deregulated 
in at least one treatment is shown in Fig. 6B. Detailed heat maps of differentially expressed proteins are reported 
in Supplementary Figure S9: a limited number of total proteins significantly differed between untreated WM115 
and WM/PTEN (Figure S9A), while no specific phosphorylation site appeared to be modulated by stable PTEN 
transfection. Single-agent Trametinib significantly affected the expression of 20 proteins (12 as total protein 
expression and 8 as phosphorylation status) and 13 proteins (10 as total protein expression as and 3 phosphoryl-
ation status) in WM115 and WM/PTEN, respectively, with no overlap in the affected proteins, except for CHUK 
and NFκ BIα proteins which were affected by Trametinib treatment as phosphorylation status in WM115 and as 
total protein in WM/PTEN, respectively (Figure S9B and D). Single treatment with Everolimus significantly mod-
ulated the expression of 17 proteins (14 as total protein expression and 3 as phosphorylation status) and 3 proteins 
(as total protein expression) in WM115 and WM/PTEN cells, respectively, with no overlap (Figure S9C and E).
The effects of the combined treatment on protein expression profile in WM115 and WM/PTEN are shown in 
the network analysis in Fig. 6C. A considerable number of proteins were modulated in WM115, while relatively 
few changes were observed in WM/PTEN, suggesting that PTEN status can strongly influence the molecular 
response to combined treatment. Response to combined treatment also differed qualitatively, since the only pro-
tein modulated by the combination in both WM115 and WM/PTEN was CHUK, downregulated as total protein 
in both cell lines and phosphorylated on T23 in WM115 (Figure S9D). We next filtered and clustered data to high-
light changes in proteomic profiles occurring exclusively under conditions in which combined treatment resulted 
in synergistic growth inhibition (i.e. changes occurring after combined treatment in WM115, but not in clone 
WM/PTEN, and not occurring after single-agent Trametinib/Everolimus treatment in either cell line, Fig. 7A). 
With this approach, the most significant changes were observed in components of the JAK1/STAT3 network 
(both total and phosphorylated proteins), phosphorylated PAK1/2/3, and phosphorylated NFκ BIε . These results 
were validated by Western Blot assay: phosphorylated PAK1/2 (S144/141) was downregulated by Trametinib 
and combined Trametinib and Everolimus treatment more prominently in WM115 than in WM/PTEN; STAT3 
phosphorylation (S727) was strongly induced by combination treatment in WM115 and to a much lesser extent 
in WM/PTEN; phosphorylated NFκ BIε was upregulated by single and combined treatments in WM115 and only 
by Everolimus and combined treatment WM115/PTEN cells (Fig. 7B). Selective upregulation of STAT3 phospho-
rylation by combined MEK/mTOR inhibition in PTEN-loss contexts was also confirmed in isogenic HCT116 cell 
lines (HCT116 Parental and HCT116 PTEN−/−; Fig. 7C).
Discussion
The general aim of our study was to assess the molecular determinants of therapeutic synergism between MAPK 
and PI3K pathway inhibitors. In a panel of human cancer cell lines of different histological origin, including 
isogenic colorectal cancer cell lines only differing for PTEN status, PTEN-loss effectively predicted synergistic 
growth inhibitory interactions between RAF/MEK and PI3K/AKT/mTOR inhibitors. Moreover, PTEN appeared 
to play a causal role in determining pharmacological interactions between pathway inhibitors, as genetic manip-
ulation of PTEN expression in melanoma cell lines, dramatically altered the functional response to combined 
MEK/mTOR inhibition.
Combined inhibition of both the MAPK and PI3K pathways is being actively explored as an attractive ther-
apeutic strategy in oncology. Although PTEN-loss has not been formally linked to synergistic pharmacologic 
interactions between MAPK and PI3K/mTOR inhibitors, careful analysis of published evidence suggests that such 
combination provides more striking tumor control in PTEN-loss, as compared with PTEN-competent, preclinical 
models. Indeed, Kinkade et al. have demonstrated that combinatorial blockade of MEK and mTOR signaling was 
highly synergistic, as compared to single-pathway inhibition, in terms of growth and proliferation inhibition of 
castration-resistant prostate cancer in the Nkx3.1, PTEN-mutant, mouse model23. Carracedo et al. simultane-
ously reported that combined MEK and mTOR inhibition was also effective in tumor xenografts generated using 
the PTEN-competent breast cancer cell line MCF7; however, the increase in apoptotic index and the decrease 
in the percentage of Ki67-positive cells in the combined treatment group was barely additive, as compared with 
PD0325901- and Everolimus- single-treatment groups, in such PTEN wild-type context24. In line with the con-
cept that combined RAF/MEK/ERK and PI3K/AKT/mTOR inhibition is selectively synergistic in PTEN-loss 
contexts, Daphu et al. have demonstrated that combined therapy with the BRAF inhibitor Vemurafenib and the 
mTOR inhibitor Temsirolimus is highly synergistic, as compared to single-drug treatment, in cell lines derived 
from human melanoma brain metastases harboring both a BRAF mutation and PTEN-loss25. Moreover, data 
derived from a phase I clinical trial program indicate that combined MEK/mTOR targeting achieved relatively 
prolonged disease control in patients whose tumors harbored RAS/RAF alterations and simultaneous PTEN 
loss14,26.
Here we show that synergistic growth inhibitory effects are invariably observed with combined inhibition 
of the MAPK (using either BRAF or MEK inhibitors) and PI3K (using AKT, mTOR or double PI3K/mTOR 
inhibitors) pathways in cell lines lacking functional PTEN expression, suggesting that the growth inhibitory 
interactions occur at the pathway level, regardless of the specific point of the cascade being inhibited or of the 
MEK/mTOR inhibitor ratio used. Conversely, pharmacologic interactions between Trametinib and Everolimus 
are in the additive to antagonistic range in cells with an intact PTEN. The H460 lung cancer cell line constitutes 
a notable exception, as combined treatment resulted in striking synergistic growth inhibitory effects, despite 
the presence of an intact PTEN gene and protein. In this model, the presence of an LKB1/STK11 mutation may 
potentially explain these results: indeed, loss of LKB1 may lead to mTOR hyperactivation27,28, bypassing PTEN 
effects; moreover LKB1/STK11 and PTEN may interact with each other, resulting in LKB1 cytoplasmic reten-
tion and PTEN phosphorylation, although the biological significance of these modifications has not yet been 
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Figure 6. Proteomic analysis of WM115 (PTEN-loss) and WM/PTEN cells subjected to combined MEK 
and mTOR inhibition. WM115 cells stably transfected with either an empty plasmid vector (WM) or a plasmid 
encoding a GFP-tagged PTEN (WM/PTEN) were treated with Trametinib (100 nM), Everolimus (100 nM), or 
Trametinib + Everolimus (Combo) for 24 h. (A) Unsupervised Principal Component Analysis of all proteins 
deregulated by Trametinib and Everolimus, alone or in combination, in WM115 cells stably transfected with 
either an empty plasmid vector (WM) or a plasmid encoding a GFP-tagged PTEN (WM/PTEN). (B) Hierarchical 
Cluster of all deregulated proteins in at least one treatment using Trametinib (Tram), Everolimus (Eve), or the 
combination of the two drugs (Combo) in WM115and WM/PTEN cells. (C) Interaction network of the proteins 
found deregulated after combination treatment in WM115 and WM/PTEN. Network analysis was performed 
using Genemania; the resulting networks were then imported into Cytoscape in order to map fold-change values. 
Positive and negative fold changes are shown in red and green, respectively, on a scale from + 2 to − 2.
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defined29. Interestingly, LCSC1, in which combined MEK/mTOR is highly synergistic in vitro, also displays a 
LKB1/STK11 mutation. Analysis of the activation of apoptotic pathways shows that combined MEK/mTOR inhi-
bition induces apoptosis more robustly and more persistently in PTEN-loss contexts, thereby partly explaining 
therapeutic synergism in this molecular context; however, we are currently investigating whether other growth 
inhibitory and/or cell death mechanisms (e.g. cell cycle inhibition, autophagy) also contribute to the observed 
tumor inhibitory synergism, particularly in vivo.
Genetic characterization of the melanoma, lung and colorectal cancer-derived CSC models tested revealed 
no obvious mutations in the PTEN gene. However, PTEN protein was consistently expressed in MIC, while 
it is very low, as compared to more differentiated, “bulk” populations or established cell lines, in LCSC and 
CR-CSC19,22,30–32; moreover, PTEN expression levels in CSC can be modulated upon differentiation and spe-
cific treatments (Eramo, 2016, unpublished results10,19,30–32). Overall, the relationship between PTEN gene status/
protein expression and response to combined MEK/mTOR inhibition is less stringent in CSC models, possibly 
as a result of complex regulation mechanisms, encompassing transcriptional/post-transcriptional regulation, 
non-coding RNAs, post-translational modifications, protein-protein interactions, and sub-cellular localiza-
tion; this exceptionally complex regulation makes it difficult to evaluate PTEN functional status in human tum-
ors19,33–35. Although the role of PTEN expression/function in CSC needs to be studied in more detail, here we 
show that combined MEK/mTOR inhibition exerts synergistic anti-tumor activity in vitro and, most importantly, 
in vivo, in a proportion of lung and colorectal CSC-derived models. These results may be clinically relevant, as 
they raise the intriguing possibility that combined treatment could be key to selectively eliminate CSC popula-
tions, which are usually resistant to current therapeutic strategies36.
Although PTEN status profoundly affects functional response of cancer cells to single or combined MEK/mTOR 
blockade, PTEN silencing or enforced expression does not significantly alter pharmacologic response to 
Trametinib and Everolimus in terms of activation of obvious downstream targets along the respective signa-
ling cascades (see Supplementary Figure S4 and data not shown). This suggests that important mediators of 
the synergistic interactions between Trametinib and Everolimus in a PTEN-loss context may actually lie out-
side the classical MAPK and PI3K pathways. Thus, we explored global changes in phosphoproteomic profiles by 
high-throughput proteomic analysis. The most extensive modifications in protein expression/phosphorylation 
profiles in response to single or combined MEK/mTOR inhibition occurred in cells lacking functional PTEN, 
Figure 7. Hierarchical cluster of proteins deregulated after combination treatment in WM115 cell line. 
(A) Hierarchical cluster of proteins deregulated using combination treatment in WM115 and at the same 
time not deregulated with single-agent Trametinib or Everolimus treatments alone in both cell lines WM115 
and WM/PTEN. (B) WM115 and WM/PTEN were treated with Trametinib (Tram), Everolimus (Eve), or the 
combination of the two drugs. The cells were lysed and analyzed by Western Blotting using antibodies specific 
for p-PAK1/2 (S144/S141), p-STAT3 (S727), p-NFκ BIε (S22). Western blot with antibodies specific for β 
-actin are shown as protein loading and blotting control. (C) Isogenic HCT116 cell lines (HCT116 Parental 
and HCT116 PTEN−/−) were treated with Trametinib (Tram), Everolimus (Eve), or the combination of the two 
drugs and cell lysates were analyzed by Western Blotting using the indicated antibodies and β -actin was used as 
blotting control.
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whereas its enforced expression significantly blunted molecular response to treatments. Among proteins that 
are selectively modulated by combined, as compared with single-agent, treatment in the PTEN-loss WM115 cell 
line (in which combined treatment is functionally synergistic) we found PAK, NFκBIε, and kinases of the JAK/
STAT (JAK1, STAT3, MAPK14) pathway of particular potential interest. PAK act as key signal transducers in 
several cancer signaling pathways, including RAS/RAF/MAPK and PI3K/AKT. Several studies have highlighted 
the role of PAK in the phosphorylation of both RAF-1 and MEK, facilitating signaling through the RAS/RAF/
MAPK pathway37,38. On the other hand, PAK is a key mediator in the PI3K-AKT signaling axis through AKT 
phosphorylation on S473 and T308; furthermore, PAK could be directly activated by PI3K via RAC1/Cdc4539,40. 
Activation of the transcription factor NFκ B appears to be a prominent mechanism by which PAK1 potentially 
regulates survival of cancer cells40,41; consistent with the hypothesis that combined MEK/mTOR inhibition in 
PTEN-loss contexts might synergistically inhibit tumor growth by selectively modulating a PAK/NFκ B axis. 
Phosphorylation of the NFκ B inhibitor NFκ BIε42,43 was also modulated differentially by single or combined 
MEK/mTOR inhibition in PTEN-competent and PTEN-loss contexts. Recent studies have shown that in glio-
blastoma models STAT3 and PTEN activities, or lack thereof, may cooperate in modulating tumorigenesis and 
disease progression. Indeed, PTEN-mediated cooperative perturbation of AKT and STAT3 signals regulates pro-
liferation and senescence in glioblastoma cells and the transcription factor STAT3 harbors a PTEN-regulated 
tumor suppressive function in mouse astrocytes44–46. Interestingly, NFκ B and STAT3 extensively cross-regulate 
each other47 and synergistically control a common set of genes encoding for cytokines and chemokines48,49, such 
as IL-8, which may constitute a common target of the anti-tumor activity of combined MEK/mTOR inhibition in 
PTEN-loss contexts, particularly in vivo, through modulation of tumor/microenvironment interactions. Indeed, 
we have recently observed that IL-8 is overexpressed in a PTEN-loss context and downregulated in response to 
combined MAPK/PI3K inhibition in colorectal cancer models, possibly as a consequence of increased STAT3 
phosphorylation (Ciuffreda, 2016, unpublished observation).
Overall, the results obtained clearly highlight a crucial role for PTEN in determining the functional out-
come of combined MEK/mTOR inhibition. Such combination has shown substantial clinical toxicity in a recently 
completed phase I study50, where a recommended phase II dose and schedule of Trametinib in combination 
with Everolimus could not be identified. However, durable disease control was observed in approximately 30% 
of patients, suggesting that some patients may derive clinically significant benefit, even if treated with largely 
suboptimal single-agent doses. Our data suggest that PTEN status may potentially be developed as a biomarker 
of clinical situations in which combined inhibition of the MEK/ERK and PI3K/AKT/mTOR pathways could be 
highly synergistic and require reduced single-agent doses of each agent, thereby reducing toxicity. This is often 
the case, as combination drug therapies are usually more toxic than monotherapy alternatives, compromising 
quality of life, but also potentially providing survival advantages and reducing/delaying the development of drug 
resistance51,52. Indeed, the identification of the detailed molecular mechanisms and putative biomarkers of syner-
gistic therapeutic interactions will be crucial to successfully develop combination strategies in the clinical setting, 
allowing for the selection/enrichment of patients at the highest chance of benefit12,17,18.
Materials and Methods
Cell lines and plasmid transfections. All cell lines were obtained from the American Type Culture 
Collection (ATCC), with the exception of WM115 cells, which were kindly donated by Dr. Meenhard Herlyn 
(Wistar Institute, Philadelphia, USA), and C32, KM12C and SW620, which were kindly donated by Dr. Federica 
Di Nicolantonio (University of Turin, Turin, Italy). X-MAN™ HCT116 Parental and HCT116 PTEN−/− were 
generated by Horizon from homozygous knock-out of PTEN by deleting exon 5 which encodes the active site 
of the protein in the colorectal cancer cell line HCT116 (Horizon Discovery. www.horizondiscovery.com). Cell 
lines were routinely maintained in RPMI 1640 or DMEM medium supplemented with 10% fetal bovine serum 
(FBS), 2 mM L-glutamine, and antibiotics in a humidified atmosphere with 5% CO2 at 37 °C. Cell culture rea-
gents were purchased from Invitrogen (Milan, Italy). Cells were transfected with either a GFP-PTEN expression 
construct53 or SureSilencing short hairpin RNA (shRNA) plasmids against PTEN (SABiosciences, Frederick, 
USA). Transfections were performed using the TransIT-LT1 transfection reagent (Mirus Bio LLC; Madison, USA) 
according to the manufacturer’s protocol.
More information about cell proliferation assay, drugs and cells and treatments are provided in Supplementary 
Experimental Procedures.
Next-generation targeted sequencing. A custom panel to analyze all exons of PTEN gene was used. 
Details on target regions of panel are given in Supplementary Table S3 20 ng of DNA were used for each multiplex 
PCR amplification. The quality of the obtained libraries was evaluated by the Agilent 2100 Bioanalyzer on-chip 
electrophoresis (Agilent Technologies). Emulsion PCR was performed with the Ion OneTouch™ OT2 System 
(Life Technologies). Sequencing was run on the Ion Proton (PI, Life Technologies) loaded with Ion PI Chip v2. 
Data analysis, including alignment to the hg19 human reference genome and variant calling, was done using the 
Torrent Suite Software v.5.0 (Life Technologies). Filtered variants were annotated using a custom pipeline based 
on vcflib (https://github.com/ekg/vcflib), SnpSift1, the Variant Effect Predictor (VEP) software2 and NCBI RefSeq 
database. A baseline for CNV detection was performed using 10 normal male DNA extracted from fresh frozen 
tissues. Copy number variation analysis of gene was performed using adequate pipeline using IonReporter 5.0 
version (Life Technologies).
Melanoma, Lung and Colorectal cancer stem cells: isolation, culture and treatment. MIC 
and LCSC were derived from tumor samples obtained in accordance with procedures and protocols approved 
by the internal review board of the Sant’Andrea Hospital, University of Rome “La Sapienza”, as described else-
where20–22,54. CR-CSC were obtained in accordance with procedures and protocols approved by the internal 
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review board of Department of Surgical and Oncological Sciences (University of Palermo) as described else-
where31,32. All patients signed an informed consent form. The use of such material was formally approved by the 
Ethical Committee/Institutional Review Board of the Regina Elena National Cancer Institute, National Institutes 
of Health prior and University of Palermo to the commencement of the study.
More information on CSC generation, culture, and validation, including antibodies and reagents is provided 
in Supplementary Methods.
Xenografts. Female CD-1 nude (nu/nu) mice, 6 to 8 weeks old, were used (Charles River Laboratories, Calco, 
Italy). Mice were housed under pathogen-free conditions and all procedures involving animals and their care 
were in accordance with national and international law sand policies. Solid tumors were obtained by intramus-
cular injection of 5 or 7 × 106 viable cells for M14 and C32, respectively. Each experimental group included 8 to 
10 animals. Trametinib was formulated in 0.5% hydroxypropyl methylcellulose plus 0.2% Tween 80 and admin-
istered by oral gavage at the dosage of 0.2 mg/kg per day. Everolimus was administrated by gavage at the dosage 
of 2 mg/kg per day. Mice treated with an equal amount of vehicle were used as control groups. Treatment started 
when the tumor mass reached palpability (approximately 200 mg), and drugs were administered daily for 13 days; 
tumor size was measured every 2 to 3 days. We chose doses of Trametinib and Everolimus at the lower end of 
previously published evidence55,56 in vivo studies, in order to better assess therapeutic synergism and minimize 
toxicity in the combination group. Mice were killed when tumor volume reached more than 2000 mg, and tumors 
were excised and placed in 10% buffered formaldehyde. Tumor weight was calculated from caliper measurements 
according to the following formula: tumor weight (mg) = length (mm) × width (mm)2/2. In xenograft experi-
ments carried out in CR-CSC-derived models Trametinib 0.3 mg/kg and Everolimus 2 mg/kg were used.
The three R’s principles were followed in planning and conducting all experiments involving live animals; 
the in vivo experimental plan was revised and formally approved by the Ethical Committee/Institutional Review 
Board of the Regina Elena National Cancer Institute and of the University of Palermo.
Western blot analysis. In all cell lines tested, PTEN protein expression was assessed using Western blot 
assay. For western blotting, total cell lysates were prepared as described previously57. More information on this 
method including antibodies and reagents is provided in Supplementary Methods.
Proteomic Analysis. For pan-specific and phosphosite-specific antibody microarray analysis, cells were 
lysed using a lysis buffer [1% NP 40, 20 mM HEPES (pH 7.4), and 2 mM EDTA] containing phosphatase inhib-
itors (100 mM NaF, 10 mM Na4P2O7, 1 mM NaVO3 and 1 mM molybdate), protease inhibitors (10 μ M leu-
peptin, 10 μ g/ml aprotinin, and 1 mM PMSF) and disulphide reducing agent (1 mM dithiothreitol). The final 
protein concentration in SDS-PAGE sample buffer was adjusted to 1 mg/ml. Samples were analyzed by Kinexus 
Bioinformatics Corporation (Vancouver, British Columbia, Canada). A complete list of unique target proteins 
and phospho-sites tracked in the microarray is available at http://www.kinexus.ca. More information about pro-
teomic analysis can be found in Supplemental Experimental Procedures.
Statistical Analysis. Differences between the groups were analyzed with a 2-tailed Student’s t test for paired 
samples. Associations were analyzed by Chi Square or Fisher’s Exact test, as appropriate. Correlations between 
treatment effects and genetic aberrations were analyzed according to Mann-Whitney (non parametric) tests. 
Significance was defined at the p < 0.05. The SPSS® (21.0) statistical program was used for all analyses. Synergism, 
additivity, and antagonism were assessed by isobologram analysis with a fixed-ratio experimental design using 
the Chou-Talalay method58. Results were analyzed with the Calcusyn software (Biosoft, Cambridge, United 
Kingdom) and combination indexes (CI) were appropriately derived. By this method, an average CI at the ED50, 
ED75, and ED90 < 1 indicates synergism, = 1 indicates additivity, and > 1 indicates antagonism, respectively.
All the experimental methods were performed in accordance with the institutional National and International 
guidelines and regulations.
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